Sibutramine and L-carnitine compared to sibutramine alone on insulin resistance in diabetic patients

Internal Medicine

Volumn 49, Issue 16, 2010, Pages 1717-1725

  Derosa, Giuseppe ^a   Maffioli, Pamela ^a   Salvadeo, Sibilla A T ^a   Ferrari, Ilaria ^a   Gravina, Alessia ^a   Mereu, Roberto ^a   D'Angelo, Angela ^a   Palumbo, Ilaria ^a   Randazzo, Sabrina ^a   Cicero, Arrigo F G ^b  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Insulin resistance; L carnitine; Resistin; Sibutramine; Type 2 diabetes

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE; C REACTIVE PROTEIN; CARNITINE; CHOLESTEROL; EXENDIN 4; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLITAZONE DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INCRETIN; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; NATEGLINIDE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; REPAGLINIDE; RESISTIN; RETINOL BINDING PROTEIN 4; ROSIGLITAZONE; SIBUTRAMINE; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL; UNINDEXED DRUG;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CALORIC RESTRICTION; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

BLOOD GLUCOSE; CARNITINE; CYCLOBUTANES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EXERCISE; FEMALE; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED;

EID: 77956224331     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.49.3401     Document Type: Article

References (48)

1. Fried M, Hainer V, Basdevant A, et al. Interdisciplinary European guidelines on surgery for severe obesity. Rozhl Chir 87: 468-476, 2008.
2. Pagotto U, Vanuzzo D, Vicennati V, Pasquali RG. Pharmacological therapy of obesity. G Ital Cardiol (Rome) 9 (4 Suppl 1): 83S-93S, 2008.
3. Marović D. Elevated body mass index fatty liver. Srp Arh Celok Lek 136: 122-125, 2008 (in Serbian).
4. Lavie CJ, Artham SM, Milani RV, Ventura HO. The obesity paradox: impact of obesity on the prevalence prognosis of cardiovascular diseases. Postgrad Med 120: 34-41, 2008.
5. Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 369: 71-77, 2007.
6. Arterburn DE, Crane PK, Veenstra DL. The efficacy and safety of sibutramine for weight loss: a systematic review. Arch Intern Med 164: 994-1003, 2004.
7. Rebouche CJ, Bosch EP, Chenard CA, Schabold KJ, Nelson SE. Utilization of dietary precursors for carnitine synthesis in human adults. J Nutr 119: 1907-1913, 1989.
8. Newsholme EA, Leech AR. Biochemistry for Medical Sciences. John Wiley and Sons, Chichester, 1983: 318-321.
9. Uziel G, Garavaglia B, Di Donato S. Carnitine stimulation of pyruvate dehydrogenase complex (PDHC) in isolated human skeletal muscle mitochondria. Muscle Nerve 11: 720-724, 1988.
10. Amat di San Filippo C, Taylor MR, Mestroni L, Botto LD, Longo N. Cardiomyopathy carnitine deficiency. Mol Genet Metab 94: 162-166, 2008.
11. Rydén L, Standl E, Bartnik M, et al. Guidelines on diabetes, prediabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 28: 88-136, 2007.
12. World Health Organization. Obesity: preventing and managing the global epidemic. Report of WHO consultation on obesity. WHO, Geneva, 1997.
13. Lichtenstein AH, Appel LJ, Brands M, et al. Summary of American Heart Association Diet and Lifestyle Recommendations Revision 2006. Arterioscler Thromb Vasc Biol 26: 2186-2191, 2006.
14. Bunn HF, Gabbay KH, Gallop PM. The glycosylation of haemoglobin. Relevance to diabetes mellitus. Science 200: 21-27, 1978.
15. European Diabetes Policy Group. A desktop guide to type 2 diabetes mellitus. Diabet Med 16: 716-730, 1999.
16. Heding LG. Determination of total serum insulin (IRI) in insulintreated diabetic patients. Diabetologia 8: 260-266, 1972.
17. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419, 1985.
18. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 27: 1487-1495, 2004.
19. Klose S, Borner K. Enzymatische Bestimmung des Gesamtcholesterins mit dem Greiner Selective Analyzer (GSA II). [Enzymatic determination of total cholesterol with the Greiner Selective Analyzer GSA-II]. J Clin Chem Clin Biochem 15: 121-130, 1978 (in German).
20. Wahlefeld AW. Triglyceride determination after enzymatic hydrolysis. In: Methods of Enzymatic Analysis. 2nd English ed. Academic Press, Inc., New York, 1974: 18-31.
21. Havel RJ, Edr HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 34: 1345-1353, 1955.
22. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein in plasma, without use of the preparative ultracentrifuge. Clin Chem 18: 499-502, 1972.
23. Takebayashi K, Suetsugu M, Wakabayashi S, Aso Y, Inumai T. Retinol binding protein-4 and clinical features of type 2 diabetes patients. J Clin Endocrinol Metab 92: 2712-2719, 2007.
24. Yannakoulia M, Yiannakouris N, Bluher S, Matalas AL, Klimis-Zacas D, Mantzoros CS. Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans. J Clin Endocrinol Metabol 88: 1730-1736, 2003.
25. Korner A, Garten A, Bluher M, Tauscher R, Kratzsch J, Kiess W. Molecular characteristics of serum visfatin and differential detection by immunoassays. J Clin Endocrinol Metab 92: 4783-4791, 2007.
26. Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem 45: 2136-2141, 1999.
27. Winer BJ. Statistical Principles in Experimental Design. 2nd ed. McGraw-Hill, New York, 1971.
28. Derosa G, D'Angelo A, Salvadeo SAT, et al. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone. Metabolism 57: 1552-1557, 2008.
29. Derosa G, Mereu R, Salvadeo SAT, et al. Pioglitazone metabolic effect in metformin-intolerant obese patients treated with sibutramine. Intern Med 48: 265-271, 2009.
30. Mingrone G, Greco AV, Capristo E, et al. L-carnitine improves glucose disposal in type 2 diabetic patients. J Am Coll Nutr 18: 77-82, 1999.
31. Derosa G, Cicero AFG, Gaddi A, Mugellini A, Ciccarelli L, Fogari R. The effect of L-carnitine on plasma lipoprotein(a) levels in hypercholesterolemic patients with type 2 diabetes mellitus. Clin Ther 25: 1429-1439, 2003.
32. Sirtori CR, Calabresi L, Ferrara S, et al. L-carnitine reduces plasma lipoprotein(a) levels in patients with hyper Lp(a). Nutr Metab Cardiovas Dis 10: 247-251, 2000.
33. Li YB, Zhu DL, Tian HM, et al. Characteristics of dysfunction of islet beta-cell in newly diagnosed type 2 diabetic patients. Zhonghua Yi Xue Za Zhi 86: 2537-2541, 2006 (in Chinese).
34. Gavrilova O, Marcus-Samuels B, Graham D, et al. Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. J Clin Invest 105: 271-278, 2000.
35. Seppälä-Lindroos A, Vehkavaara S, Häkkinen AM S, et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 87: 3023-3028, 2002.
36. Goto T, Onuma T, Takebe K, Kral JG. The influence of fatty liver on insulin clearance and insulin resistance in non-diabetic Japanese subjects. Int J Obes Relat Metab Disord 19: 841-845, 1995.
37. Strang BD, Bertics SJ, Grummer RR, Armentano LE. Relationship of triglyceride accumulation to insulin clearance and hormonal responsiveness in bovine hepatocytes. J Dairy Sci 81: 740-747, 1998.
38. McGarry J. Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 51: 7-18, 2002.
39. Cho YM, Youn BS, Lee H, et al. Plasma retinol-binding protein-4 concentrations are elevated in human subjects with impaired glucose tolerance and type 2 diabetes. Diabetes Care 29: 2457-2461, 2006.
40. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature (London) 409: 307-312, 2001.
41. Satoh H, Nguyen MT, Miles PD, Imamura T, Usui I, Olefsky JM. Adenovirus-mediated chronic 'hyper-resistinemia' leads to in vivo insulin resistance in normal rats. J Clin Invest 114: 224-231, 2004.
42. Rangwala SM, Rich AS, Rhoades B, et al. Abnormal glucose homeostasis due to chronic hyperresistinemia. Diabetes 53: 1937-1941, 2004.
43. Reilly MP, Lehrke M, Wolfe M, Rohatgi A, Lazar MA, Rader DJ. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 111: 932-939, 2005.
44. Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307: 426-430, 2005.
45. Hug C, Lodish HF. Visfatin: a new adipokine. Science 307: 366-367, 2005.
46. Zwacka TP, Hornbach V, Torzewski J. C-reactive protein-mediated lipoprotein uptake by macrophages. Circulation 103: 1194-1197, 2001.
47. Derosa G, Cicero AFG, Murdolo G, et al. Efficacy and safety comparative evaluation of or 1. listat and sibutramine treatment in hypertensive obese patients. Diabetes Obes Metab 7: 47-55, 2005.
48. Derosa G, Cicero AF, Murdolo G, Ciccarelli L, Fogari R. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients. Diabetes Nutr Metab 17: 222-229, 2004.